NZ239308A - Process for producing solid oral dosage forms of loperamide and dosage forms thus formed - Google Patents

Process for producing solid oral dosage forms of loperamide and dosage forms thus formed

Info

Publication number
NZ239308A
NZ239308A NZ239308A NZ23930891A NZ239308A NZ 239308 A NZ239308 A NZ 239308A NZ 239308 A NZ239308 A NZ 239308A NZ 23930891 A NZ23930891 A NZ 23930891A NZ 239308 A NZ239308 A NZ 239308A
Authority
NZ
New Zealand
Prior art keywords
loperamide
solid oral
dosage form
compound
oral dosage
Prior art date
Application number
NZ239308A
Other languages
English (en)
Inventor
Daniel Louis Barone
Shawn Alan Denny
Francis Bernard Chapura
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NZ239308A publication Critical patent/NZ239308A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ239308A 1990-08-09 1991-08-08 Process for producing solid oral dosage forms of loperamide and dosage forms thus formed NZ239308A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56501090A 1990-08-09 1990-08-09

Publications (1)

Publication Number Publication Date
NZ239308A true NZ239308A (en) 1994-04-27

Family

ID=24256836

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ239308A NZ239308A (en) 1990-08-09 1991-08-08 Process for producing solid oral dosage forms of loperamide and dosage forms thus formed

Country Status (9)

Country Link
EP (1) EP0542879A1 (fi)
JP (1) JPH06500104A (fi)
AU (1) AU661972B2 (fi)
CA (1) CA2088273C (fi)
FI (1) FI930536A (fi)
IE (1) IE912815A1 (fi)
NZ (1) NZ239308A (fi)
PT (1) PT98612A (fi)
WO (1) WO1992002223A1 (fi)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
US10508373B2 (en) 2016-05-13 2019-12-17 Nike, Inc. Embroidered article

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1332236C (en) * 1985-10-11 1994-10-04 Lourens Wals –,-–-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, n-oxides
DE3906779A1 (de) * 1989-03-03 1990-09-06 Hoechst Ag Mittel gegen tierparasiten
GB8908361D0 (en) * 1989-04-13 1989-06-01 Beecham Group Plc Composition
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament

Also Published As

Publication number Publication date
FI930536A0 (fi) 1993-02-08
AU8440091A (en) 1992-03-02
AU661972B2 (en) 1995-08-17
IE912815A1 (en) 1992-02-12
CA2088273A1 (en) 1992-02-10
FI930536A (fi) 1993-02-08
CA2088273C (en) 1996-05-14
JPH06500104A (ja) 1994-01-06
EP0542879A1 (en) 1993-05-26
WO1992002223A1 (en) 1992-02-20
PT98612A (pt) 1992-06-30

Similar Documents

Publication Publication Date Title
FI122717B (fi) Menetelmä valmistaa tramadolihydrokloridia hallitusti vapauttava valmiste
JP6797980B2 (ja) ルカパリブの高投与力価錠剤
EP0108218A2 (en) Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
US6558704B1 (en) Process for preparing pellets containing up to 90 wt.% of a pharmaceutical active ingredient
KR100836960B1 (ko) 새로운 나이아신 제어방출형 제제
SK76394A3 (en) Agent with successive release of effective matter and method of its preparation
EP1886670A1 (en) Pharmaceutical compositions of memantine
CN101073563B (zh) 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片
HUE028204T2 (en) Pharmaceutical compositions containing the active ingredient nilotinib or a salt thereof
IE72095B1 (en) Antimalarial compositions
WO2021238978A1 (zh) 含硝羟喹啉前药的药物组合物及其制备方法和应用
WO2006123213A1 (en) Modified release formulations of gliclazide
DE4310963C2 (de) Retardmikrotablette von beta-Phenylpropiophenonderivaten
CA2088273C (en) Processes for formulating a solid oral dosage form of loperamide compounds
CN105395507A (zh) 一种盐酸环苯扎林缓释片
DE602005000675T2 (de) Pharmazeutische Polymerformulierung zur retardierten Freisetzung von Terbutalinsulfat
CN113365611A (zh) 制备包含奈福泮和对乙酰氨基酚的药物组合物的方法和由该方法获得的药物组合物
AU2004263054B2 (en) Preparing method for controlled released type tablet tamsulosin HCl and the tablet thereof
JPH06157606A (ja) グリコサミノグリカンとアミノ酸エステルとの塩、その製造法およびそれを含有する薬学的製剤
JPH06506706A (ja) ベンゾフルメトールを含有する抗マラリア性の相乗作用組成物
Fleishaker et al. Effect of food on the bioavailability of adinazolam from a sustained release formulation: effect of meal timing and lack of dose dumping
RU2183116C1 (ru) Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием
Perumal The Preparation and In-vitro Evaluation of Sustained Release Capsules of Rivastigmine Tartrate
RU2247561C1 (ru) Комбинированная фармацевтическая композиция с противотуберкулёзным действием
CN1476841A (zh) 葛根素分散片组合物及其制备方法